KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Accumulated Expenses (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Accumulated Expenses data on record, last reported at $99.3 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 144.86% year-over-year to $99.3 million; the TTM value through Sep 2025 reached $99.3 million, up 144.86%, while the annual FY2024 figure was $108.4 million, 60.11% up from the prior year.
  • Accumulated Expenses reached $99.3 million in Q3 2025 per IONS's latest filing, up from $46.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $128.0 million in Q3 2022 and bottomed at $25.0 million in Q2 2022.
  • Average Accumulated Expenses over 5 years is $72.8 million, with a median of $75.7 million recorded in 2021.
  • The widest YoY moves for Accumulated Expenses: up 319.23% in 2023, down 73.61% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $88.6 million in 2021, then tumbled by 44.47% to $49.2 million in 2022, then surged by 37.72% to $67.7 million in 2023, then soared by 60.11% to $108.4 million in 2024, then dropped by 8.42% to $99.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $99.3 million in Q3 2025, $46.6 million in Q2 2025, and $102.7 million in Q1 2025.